Joint Statement from Reps. Jennifer McClellan and Emilia Sykes on Mifepristone Ruling and Ongoing Legal Uncertainty

Washington, D.C. - U.S. Representatives Jennifer McClellan (VA-04), Chair of the Abortion Rights and Access Task Force of the Reproductive Freedom Caucus, and Emilia Sykes (OH-13), Chair of the Reproductive Justice Task Force of the Reproductive Freedom Caucus, released the following joint statement:

"As Chairs of task forces within the Reproductive Freedom Caucus, we are closely monitoring the case Louisiana v. FDA. Regardless of what lies in the fine print, let us be clear about one thing: mifepristone was safe and effective when the FDA first approved it over 25 years ago, and it has remained safe and effective for the millions of people who have used it to end their pregnancies and manage their miscarriages since. This is true in health care settings, and it is true at home.

"Though the Supreme Court has temporarily reinstated access to mifepristone, questions remain about how long this decision will stand and what might change going forward. We cannot allow this uncertainty to continue.

"We are deeply concerned about the lasting impacts this decision may have not only in Louisiana, but nationwide. As additional details become clear in the coming hours and days, we will continue fighting for access to reproductive health care, including medication abortion, for all people."